RADNOR, Pa., Dec. 27, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna") (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna's February 8, 2024 initial public offering ("IPO"). The lead plaintiff deadline is February 7, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Kyverna losses, you ...

Core Viewpoint - A class action securities lawsuit has been filed against Kyverna Therapeutics, Inc. alleging false statements and omissions related to its initial public offering (IPO) [1][2]. Group 1: Lawsuit Details - The complaint claims that the defendants made false statements regarding the IPO strategy, terms, and disclosures in the Offering Documents [2]. - It is alleged that the underwriter defendants should have been aware of Kyverna's undisclosed issues due to ongoing communications with the company's management and legal team [2]. Group 2: Class Definition and Participation - The lawsuit aims to recover losses for investors who purchased Kyverna common stock linked to the company's February 2024 IPO [4]. - Investors affected by the alleged securities fraud can participate without incurring out-of-pocket costs [3]. Group 3: Next Steps for Investors - Investors who suffered losses in Kyverna Therapeutics have until February 7, 2025, to request to be appointed as lead plaintiff [5]. Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [6].

SAN DIEGO, Dec. 26, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a shareholder filed a class action against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and certain of the Company's senior executives and directors who signed the Registration Statement, effective February 7, 2024, issued in connection with the Company's initial public offering ("IPO"). Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.For more in ...

RADNOR, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 202 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Kyverna Therapeutics, Inc. common stock during its IPO on February 8, 2024, about the upcoming lead plaintiff deadline of February 7, 2025 [1] Group 1: Class Action Information - Investors who bought Kyverna common stock may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - To serve as lead plaintiff, individuals must file a motion with the Court by February 7, 2025 [3] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] Group 3: Case Details - The lawsuit claims that Kyverna's IPO registration statement and prospectus contained misstatements and omissions regarding the clinical trial results of its lead product candidate, KYV-101 [5] - Kyverna allegedly highlighted patient "improvement" while failing to disclose adverse data known at the time of the IPO, leading to investor damages when the true information became public [5]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Kyverna Therapeutics, Inc. regarding a class action lawsuit related to the company's initial public offering (IPO) in February 2024, alleging misleading statements and omissions in the offering documents [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals who purchased or acquired Kyverna common stock during the class period associated with the February 2024 IPO [2]. - Allegations include that the defendants issued materially false and misleading statements and failed to disclose critical information regarding the IPO strategy, terms, and disclosures in the offering documents [3]. - The complaint suggests that the underwriter defendants should have been aware of Kyverna's undisclosed issues due to ongoing communications with the company's management and legal representatives [3]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by February 7, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Viewpoint - Investors suffering losses from Kyverna Therapeutics, Inc. are encouraged to participate in a class action lawsuit due to alleged securities fraud related to undisclosed adverse data from clinical trials [4][5]. Group 1: Class Action Details - The class period for the lawsuit begins from the February 2024 IPO [3]. - The deadline for lead plaintiffs to come forward is set for February 7, 2025 [3]. - Investors do not need to take any immediate action to be part of the class action; they can choose to retain counsel or remain absent [3]. Group 2: Allegations Against Kyverna - The complaint alleges that Kyverna failed to disclose adverse data related to one of its clinical trials [5]. - It is claimed that the company withheld this adverse data, which misled investors regarding the company's business and operational prospects [5]. - The positive statements made by the company about its operations were allegedly materially misleading and lacked a reasonable basis [5].

LOS ANGELES, Dec. 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ: KYTX) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to co ...

NEW YORK, Dec. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=117784&from=4 CLASS PERIOD: ...

Core Viewpoint - A class action lawsuit has been filed against Kyverna Therapeutics, Inc. for alleged securities fraud and unlawful business practices [1][3]. Group 1: Class Action Details - The class action lawsuit is initiated by Pomerantz LLP, and shareholders who acquired DMC securities during the Class Period can request to be appointed as Lead Plaintiff by February 7, 2025 [2][3]. - A copy of the Complaint is available at Pomerantz's website [2]. Group 2: Company Background and IPO - Kyverna Therapeutics conducted its initial public offering (IPO) on February 8, 2024, offering 14.5 million shares at a price of $22.00 per share [4]. - On the same day, the company disclosed adverse data from a clinical trial, leading to a significant drop in stock price [5]. Group 3: Stock Performance - Following the adverse disclosures, Kyverna's stock price fell by $4.91, or 34%, closing at $9.53 per share on June 14, 2024 [5].